Concerning the evaluation agent for the health disparities and community grant program.
Summary
HB 26-1390 changes how Colorado evaluates the health disparities and community grant program. Under current law, the program’s effectiveness is evaluated by a third-party grant recipient selected by the state board. This bill removes that third-party evaluation requirement and instead directs the Department of Public Health and Environment to evaluate the program’s effectiveness each grant cycle.
The bill also requires the department to produce a report after each evaluation and make the report publicly available. It specifies that the evaluation must be separate from the evaluation of the cancer, cardiovascular disease, and chronic pulmonary disease prevention, early detection, and treatment program. The measure is framed as an administrative and oversight change rather than a substantive change to grant eligibility or program funding priorities.
Impact
The bill amends Colorado Revised Statutes section 25-4-2203 and section 25-20.5-305 to shift evaluation responsibility from an outside grant recipient to the Department of Public Health and Environment. It preserves the requirement that the program be evaluated each fiscal year/grant cycle and that evaluation costs be funded from the prevention, early detection, and treatment fund. The bill affects the administration of the health disparities and community grant program and the entities involved in its oversight, but it does not appear to change the underlying grant program structure or beneficiary eligibility.
Sentiment
The available legislative record suggests little overt controversy around the bill. It advanced through the appropriations process and was ultimately signed by the governor, which indicates broad institutional support. Because there are no committee transcripts or recorded votes provided, the public or committee-level debate cannot be assessed in detail, but the bill’s progress suggests it was generally viewed as a routine administrative refinement.
Contention
The main point of potential contention is the shift away from an independent third-party evaluator toward an internal departmental evaluation. Supporters may view this as a more direct, efficient, and consistent oversight mechanism, while critics could question whether an agency evaluating its own program provides the same level of independence. Another possible issue is the bill’s requirement that the evaluation be separate from the cancer and chronic disease program evaluation, which may affect workload and administrative costs, though the bill continues to require funding from the existing fund.